Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Stock data | 2023 | Change |
---|---|---|
Price | $12.75 | N/A |
Market Cap | $2.51B | N/A |
Shares Outstanding | 196.56M | 0.00% |
Employees | 14.59K | N/A |
Shareholder Equity | 43.70B | -16.56% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.73 | N/A |
P/S Ratio | 3.82 | N/A |
P/B Ratio | 0.06 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0009 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $655.31M | N/A |
Earnings | $40.75M | N/A |
EPS | 17.40 | N/A |
Earnings Yield | 1.36 | N/A |
Gross Margin | 0.6321 | N/A |
Operating Margin | 0.0825 | N/A |
Net income margin | 0.0622 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $736.70M | N/A |
Total Debt | $86.03M | N/A |
Cash on Hand | $10.98M | N/A |
Debt to Equity | 0.0049 | 15.25% |
Cash to Debt | 0.1276 | -1.31% |
Current Ratio | $1.78 | 6.67% |